Establishing a robust radioligand therapy program: A practical approach for North American centers.
nuclear medicine
program implementation
radioligand therapy
radiopharmaceuticals
theranostics
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
revised:
08
11
2023
received:
07
03
2023
accepted:
21
11
2023
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including gastroenteropancreatic neuroendocrine tumors, lymphoma, and most recently, advanced prostate cancer. In the United States, patient access to this therapy is currently variable. Implementation of new RLT programs and expansion of existing programs are needed to broaden patient access to and standardize the delivery of RLT, especially as new therapies are introduced into clinical practice. Drawing from experience in establishing RLT programs in different settings, we have developed practical recommendations for building and implementing a robust RLT program. In this review, we present our recommendations for minimal requirements and optimal requirements, as well as system considerations, and special issues associated with implementing an RLT program in North American centers.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Novartis Pharmaceuticals Corporation
Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
The Health Policy Partnership. Health system readiness for radioligand therapy in the US: situation analysis report. 2021. Accessed July 27, 2023. https://www.healthpolicypartnership.com/app/uploads/Health-system-readiness-for-radioligand-therapy-in-the-US-situation-analysis-report.pdf
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-135.
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578-2584.
Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-DOTATATE plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752-1763.
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
Pryma DA, Chin BB, Noto RB, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60:623-630.
Abbott A, Sakellis CG, Andersen E, et al. Guidance on 177Lu-DOTATATE peptide receptor radionuclide therapy from the experience of a single nuclear medicine division. J Nucl Med Technol. 2018;46:237-244.
Garg AK. Community-based cancer care quality and expertise in a COVID-19 era and beyond. Am J Clin Oncol. 2020;43:537-538.
Copur MS, Ramaekers R, Gönen M, et al. Impact of the National Cancer Institute Community cancer centers program on clinical trial and related activities at a community cancer center in rural Nebraska. J Oncol Pract. 2016;12:67-68.
Herrmann K, Giovanella L, Santos A, et al. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. J Nucl Med. 2022;49:2300-2309.
Medical physics staffing needs in diagnostic imaging and radionuclide therapy: an activity based approach: IAEA Human Health Reports No. 15. Vienna, International Atomic Energy Agency. 2018. International Atomic Energy Agency (IAEA) website. Accessed July 27, 2023. https://www.iaea.org/publications/12208/medical-physics-staffing-needs-in-diagnostic-imaging-and-radionuclide-therapy-an-activity-based-approach
European guidelines on medical physics expert. Annex 2. Medical Physics Expert Staffing Levels in Europe. Radiation Protection No. 174. European Commission website. Accessed July 27, 2023. https://energy.ec.europa.eu/system/files/2014-11/rp174_annex2_1.pdf
Radionuclide Therapy for Patients with Neuroendocrine Tumours (NETs) in Ontario: Expert Panel Report. 2011. Cancer Care Ontario website. Accessed July 27, 2023. https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/3171
Clinical Radiopharmaceutical Therapy Center of Excellence. Society of Nuclear Medicine and Molecular Imaging website. Accessed July 27, 2023. https://therapy.snmmi.org/SNMMI-THERAPY/Clinical_Radiopharmaceutical_Therapy_Center_of_Excellence.aspx
Avdic D, Lundborg P, Vikstrom J. Estimating returns to hospital volume: evidence from advanced cancer surgery. J Health Econ. 2019;63:81-99.
Hillner B, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18:2327-2340.
Agreement state program. US Nuclear Regulatory Commission website. Accessed July 27, 2023. https://www.nrc.gov/about-nrc/state-tribal/agreement-states.html
Baldwin JA, Bag AK, White SL, Palot-Manzil FF, O'Malley JP. All you need to know as an authorized user. AJR Am J Roentgenol. 2015;205:251-258.
Burkett BJ, Dundar A, Young JR, et al. How we do it: a multidisciplinary approach to 177Lu DOTATATE peptide receptor radionuclide therapy. Radiology. 2021;298:261-274.
Buatti JM, Pryma DA, Kiess AP, et al. A framework for patient-centered pathways of care for radiopharmaceutical therapy: an ASTRO consensus document. Int J Radiat Oncol Biol Phys. 2021;109:913-922.
Wale DJ, Viglianti BL, Gross MD, Ferretti A, Rubello D, Wong KK. Nuclear medicine therapy with 223radium-dichloride for osseous metastases in prostate carcinoma. Am J Clin Oncol. 2019;42:99-106.
O'Brien SR, Pryma DA. Managing a high-specific-activity Iobenguane therapy clinic: from operations to reimbursement. J Nucl Med. 2022;63(2):196-198.
Novartis AG. Lutathera Prescribing Information. 2023. Accessed July 27, 2023. https://www.novartis.com/us-en/sites/novartis_us/files/lutathera.pdf
Love C, Desai NB, Abraham T, et al. ACR-ACNM-ASTRO-SNMMI practice parameter for Lutetium-177 (Lu-177) DOTATATE therapy. Am J Clin Oncol. 2022;45(6):233-242.
Sanli Y, Simsek DH, Sanli O, Subramaniam RM, Kendi AT. 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer. Biomedicine. 2021;9:430.
Xofigo (radium Ra 223 dichloride injection) [prescribing information]. Bayer Pharmaceuticals, Inc. 2019. Accessed July 27, 2023. https://labeling.bayerhealthcare.com/html/products/pi/Xofigo_PI.pdf
I-131 MIBG therapy. Society of Nuclear Medicine and Molecular Imaging website. Accessed July 27, 2023. https://www.snmmi.org/Patients/Procedures/Content.aspx?ItemNumber=14795
AZEDRA Patient Brochure. Progenics Pharmaceuticals, Inc., a Lantheus company; 2021. Accessed July 27, 2023. https://www.azedra.com/content/pdf/AZEDRA_Patient_Brochure.pdf
Azedra (iobenguane I 131) [prescribing information]. Progenics Pharmaceuticals, Inc., a Lantheus company; 2021. Accessed July 27, 2023. https://www.azedra.com/content/pdf/full-prescribing-information.pdf
Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19:534-550.
Jha A, Taïeb D, Carrasquillo JA, et al. High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2021;27:2989-2995.
Zahid A, Johnson DR, Kizilbash SH. Efficacy of 177Lu-DOTATATE therapy in the treatment of recurrent meningioma. Mayo Clin Proc Innov Qual Outcomes. 2021;5:236-240.
Sistani G, Sutherland DEK, Mujoomdar A, et al. Efficacy of 177Lu-DOTATATE induction and maintenance therapy of various types of neuroendocrine tumors: a phase II registry study. Curr Oncol. 2020;28:115-127.
Mittra ES. Neuroendocrine tumor therapy: 177Lu-DOTATATE. AJR Am J Roentgenol. 2018;211:278-285.
Eberlein U, Cremonesi M, Lassmann M. Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med. 2017;58(suppl 2):97S-103S.
Pandit-Taskar N, Iravani A, Lee D, et al. Dosimetry in clinical radiopharmaceutical therapy of cancer: practicality versus perfection in current practice. J Nucl Med. 2021;62(suppl 3):60S-72S.